ALNYLAM PHARMACEUTICALS INC (ALNY)       204.15  +6.76 (+3.42%)

204.15  +6.76 (+3.42%)

US02043Q1076 - Common Stock

EPS Estimates (USD)

Recent Earnings VS Estimates
Period Reported Estimate Difference Surprise Q2 2022 -2.29 -1.67 -0.62-37.39% Q1 2022 -2.00 -1.88 -0.12-6.57% Q4 2021 -2.16 -1.57 -0.59-37.46% Q3 2021 -1.64 -1.60 -0.04-2.56% Q2 2021 -1.61 -1.65 0.042.16% Q1 2021 -1.71 -1.76 0.053.03% Q4 2020 -2.09 -1.74 -0.35-19.89% Q3 2020 -2.18 -1.67 -0.51-30.49%
Future EPS Estimates
Period Estimate Prior Growth (Y2Y) FY 2022 -7.58 -7.12 -6.41%Q3 2022 -1.81 -1.64 -10.48%Q4 2022 -1.73 -2.16 19.90%FY 2023 -4.34 -7.58 42.68%Q1 2023 -1.65 -2.00 17.70%Q2 2023 -1.61 -2.29 29.85%Q3 2023 -1.50 -1.81 17.01%Q4 2023 -1.27 -1.73 26.48%FY 2024 0.00 -4.34 100.00%Q1 2024 -0.96 -1.65 41.75%Q2 2024 -0.79 -1.61 51.11%Q3 2024 -0.63 -1.50 57.95%Q4 2024 -0.64 -1.27 49.48%FY 2025 0.00 0.00 -67.98%FY 2026 0.00 0.00 -71.34%

Revenue Estimates (USD)

Recent Revenue VS Estimates
Period Reported Estimate Difference Surprise Q2 2022 224.818M 261.001M -36.183M-13.86% Q1 2022 213.259M 248.241M -34.982M-14.09% Q4 2021 258.535M 238.296M 20.239M8.49% Q3 2021 187.633M 223.067M -35.434M-15.89% Q2 2021 220.553M 196.66M 23.893M12.15% Q1 2021 177.6M 172.11M 5.49M3.19% Q4 2020 163.6M 149.736M 13.864M9.26% Q3 2020 125.9M 123.169M 2.731M2.22%
Future Revenue Estimates
Period Estimate Prior Growth (Y2Y) FY 2022 1.095B 844.287M 29.75%Q3 2022 299.004M 187.633M 59.36%Q4 2022 341.429M 258.535M 32.06%FY 2023 1.658B 1.095B 51.34%Q1 2023 334.893M 213.259M 57.04%Q2 2023 361.575M 224.818M 60.83%Q3 2023 403.194M 299.004M 34.85%Q4 2023 459.059M 341.429M 34.45%FY 2024 2.417B 1.658B 45.79%Q1 2024 495.289M 334.893M 47.89%Q2 2024 529.346M 361.575M 46.40%Q3 2024 564.498M 403.194M 40.01%Q4 2024 596.722M 459.059M 29.99%FY 2025 3.521B 2.417B 45.65%FY 2026 5.23B 3.521B 48.57%